Virtual Toxicity Teams

As immunotherapies are increasingly used for patients with difficult-to-treat cancers, oncologists are challenged to identify the specialist expertise they need to address the immune-related adverse events (irAEs) that can accompany these therapies. While cancer programs seek to build effective strategies to create a team approach toward managing irAEs, some are creating a virtual space in which multiple specialists can connect and discuss how best to address the toxicities that can arise when patients receive immunotherapy for cancer. This three article series explores how the cancer programs at Johns Hopkins University, Cleveland Clinic, and Jefferson Health are taking similar yet unique approaches to recruiting specialists outside the field of oncology to participate in immunotherapy toxicity teams both in-person and virtually.